EN DE

Qianhai Health Holdings (0911) Fair Value & Analysis

Healthcare · HK · Market cap HK$108M

QH Qianhai Health Holdings 0911 · HK
PriceHK$0.5300
Fair ValueHK$0.8900
Upside+67.9%
Quality69/100
Watch Qianhai Health Holdings for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.9% net margin
Low debt · generates free cash flow
Ranks above peers (9/13)
Narrow moat 16/100
Evidence: High Range HK$0.6300 – HK$0.9600 Share as image

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 2 days ago

Share price −32.9% over the past month.

A solid business, screening 68% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (HK$0.6300). The market is more pessimistic than our downside scenario.
  • Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$1.20 HK$0.0230 Fair Value HK$0.8900 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0230 – HK$1.20 · fair‑value band HK$0.6300 – HK$0.9600 · the HK$0.5300 price screens below the HK$0.8900 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Qianhai Health Holdings (0911) currently trades at HK$0.5300, while our model-based Fair Value estimate is HK$0.8900, implying the stock looks roughly 67.9% undervalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Qianhai Health Holdings generated revenue of HK$677M at a net margin of 0.9%. Revenue grew 58.1% year over year. It earns a return on equity of 1.5%. The balance sheet holds a net cash position of HK$61.0M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.6300 (bear case) to HK$0.9600 (bull case); at HK$0.5300, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high and 138% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 68%, 0911 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$2.67 HK$4.34 HK$6.70 80
Residual Income HK$1.44 HK$1.29 HK$0.8400 76
Rev-Margin DCF HK$1.46 HK$1.95 HK$2.64 74
All 24 models by family
DCF Models
FCF DCF HK$2.77 HK$4.16 HK$7.34 38
Owner Earnings HK$0.8200 HK$1.21 HK$1.85 31
5Y Revenue Exit HK$1.46 HK$1.92 HK$2.49 39
5Y EBITDA Exit HK$1.49 HK$1.99 HK$2.59 41
5Y P/E Exit HK$1.60 HK$2.26 HK$3.00 38
10Y Revenue Exit HK$1.94 HK$2.59 HK$3.41 36
10Y EBITDA Exit HK$1.96 HK$2.64 HK$3.59 37
10Y P/E Exit HK$2.03 HK$2.81 HK$3.91 35
Earnings-Based
Graham-Dodd HK$0.2400 HK$1.49 HK$2.08 54
Lynch FV HK$0.4300 HK$0.6100 HK$0.7900 50
PEG = 1.0 HK$0.4300 HK$0.6100 HK$0.7900 46
EPV HK$0.5800 HK$0.6000 HK$0.6200 59
Multiples
P/E Multiple HK$0.5800 HK$0.7700 HK$0.9600 63
P/S Multiple HK$0.4500 HK$0.6000 HK$0.7500 58
P/B Multiple HK$0.4500 HK$0.6000 HK$0.7500 55
EV/EBIT HK$0.8100 HK$0.9600 HK$1.11 53
EV/EBITDA HK$0.7400 HK$0.8700 HK$1.00 54
EV/Revenue HK$0.6700 HK$0.8000 HK$0.9300 43
Asset-Based
NCAV (Graham) HK$1.15 HK$1.55 HK$2.31 50
Growth DCF
Growth DCF HK$2.67 HK$4.34 HK$6.70 80
Rev-Margin DCF HK$1.46 HK$1.95 HK$2.64 74
Economic Profit
Residual Income HK$1.44 HK$1.29 HK$0.8400 76
ROIC Compounder HK$0.5800 HK$0.6000 HK$0.6200 72
Growth Earnings
Growth-Adj P/E HK$0.6300 HK$0.8900 HK$1.16 68

Widest divergence: DCF Models (HK$2.26) versus Economic Profit (HK$0.6000). Highest evidence: Growth DCF (80).

Notify me when 0911 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$677M
Revenue growth (YoY) +58.1%
Net margin 0.9%
Return on equity 1.5%
Free cash flow HK$38.8M FY2025
P/E ratio 16.0 as of Jul 2, 2026
More key figures
Operating margin 0.3%
EPS (TTM) HK$0.0300
EPS growth (YoY) -69.3%
Net cash HK$61.0M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 69/100

Of which business quality 70 · Market factors (momentum, volatility) 49

Profitability 34
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 67
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 10
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 63
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Qianhai Health Holdings Limited, an investment holding company, engages in the trading and sale of electronic components, and health-care products and food businesses in Hong Kong. It offers Chinese herbal medicines and other health care products; and administrative services. The company also sells health beverages, ginseng wine, and skin-care products.

Full company description

Qianhai Health Holdings Limited, an investment holding company, engages in the trading and sale of electronic components, and health-care products and food businesses in Hong Kong. It offers Chinese herbal medicines and other health care products; and administrative services. The company also sells health beverages, ginseng wine, and skin-care products. In addition, it is involved in the sale of information technology component products, including NAND flash wafer, a thin slice of semiconductor material, such as silicon, a component of flash memory integrated circuits; and embed multi-chip package memory, an electronic component containing several memory chip and other electronic components. The company was formerly known as Hang Fat Ginseng Holdings Company Limited and changed its name to Qianhai Health Holdings Limited in September 2016. Qianhai Health Holdings Limited was founded in 1989 and is based in Sheung Wan, Hong Kong. Qianhai Health Holdings Limited is a subsidiary of Explorer Rosy Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Qianhai Health Holdings reported revenue of HK$677M in FY2025 versus HK$283M in FY2021, a compound +24.3%/yr. Reported net income was HK$5.9M in FY2025.

Growth Quality 39/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$677M
Latest YoY
+30.3%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−29.9%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.3%
Avg. growth/yr (14Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.0%
Revenue +24.3%/yr
FY21 HK$283M
FY22 HK$2.0B
FY23 HK$961M
FY24 HK$520M
FY25 HK$677M
Net income
FY21 −HK$888K
FY22 −HK$234M
FY23 −HK$52.7M
FY24 HK$1.3M
FY25 HK$5.9M

Watch 0911: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Qianhai Health Holdings · Fair Value
HK$0.8900 +68%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Qianhai Health Holdings Fair Value". https://www.fairvalue-calculator.com/stock/0911

Peer Group

Drug Manufacturers - Specialty & Generic · 624 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 69 · Top 25%
Fair Value upside +68% · Top 25%
Return on equity (TTM) 2% · Below median
Return on assets 1% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 0% · Below median
Revenue growth 58% · Top 25%

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 16.0× · Cheaper than median
P/B 0.28× · Cheaper than 75% of peers
P/S (TTM) 0.16× · Cheaper than 75% of peers
P/FCF 0.4× · Cheaper than 75% of peers
EV/EBITDA 7.2× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 6
FUTURE 100 · sector 21
PAST 6 · sector 25
HEALTH 100 · sector 97
DIVIDEND 0 · sector 31

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Qianhai Health Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Qianhai Health Holdings (0911) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$0.5300, about +68% (undervalued).
What is the fair value of 0911?
Our model-based fair value for Qianhai Health Holdings is HK$0.8900 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.5300.
What is the quality score of 0911?
Qianhai Health Holdings has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Qianhai Health Holdings (0911)?
Qianhai Health Holdings reported trailing-twelve-month revenue of about HK$677M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 0911?
The net profit margin of Qianhai Health Holdings is about 0.9%, meaning it keeps roughly 0.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Qianhai Health Holdings and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.